<DOC>
	<DOCNO>NCT01179737</DOCNO>
	<brief_summary>The purpose trial establish safety , tolerability PK nilotinib population test hypothesis 6 month treatment nilotinib significantly reduce pulmonary artery resistance .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Pharmacokinetics ( PK ) Nilotinib ( AMN107 ) Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>The purpose trial establish safety , tolerability PK nilotinib population test hypothesis 6 month</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>World Health Organization ( WHO ) Functional Class II III 6MWD ≥ 150 ≤ 450 screen Current diagnosis PAH accord Dana Point 2008 Meeting Inadequate clinical response one class ( e ) PAH drug Stabilization pulmonary hypertension medication ≥ 2 month approve therapeutic dose least one PAH drug still symptomatic WHO functional Class II III performance . Women childbearing potential practice birth control In treatment chronic nitric oxide therapy Preexisting lung disease Use drug prolong QT interval strong CYP3A4 inhibitor Long QT syndrome QTc &gt; 450 m male ; &gt; 470 m female . WHO Class IV Pulmonary capillary wedge pressure &gt; 15 mm Hg Other diagnosis PAH WHO Diagnostic Group 1 PAH associate : venous hypertension ( WHO Diagnostic Group II ) , hypoxia ( WHO Diagnostic Group III ) , chronic pulmonary thromboembolic disease ( WHO Diagnostic Group IV ) miscellaneous cause ( WHO Diagnostic Class V , include sarcoidosis , histiocytosis X , lymphangiomatosis , compression pulmonary vessel ) Thrombocytopenia &lt; 50 x109/L ( 50 x 103/µL ) Uncontrolled systemic arterial hypertension , systolic &gt; 160 mm Hg diastolic &gt; 90 mm Hg Any advance , severe , unstable disease type may interfere primary secondary endpoint evaluation . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>6MWD</keyword>
	<keyword>Pulmonary Hypertension</keyword>
</DOC>